基孔肯雅病毒衣壳蛋白的开发:抗病毒治疗开发的重点靶点

IF 2.5 4区 医学 Q3 VIROLOGY
Kavitha Karunakaran, Abdul Ajees Abdul Salam, Piya Paul Mudgal
{"title":"基孔肯雅病毒衣壳蛋白的开发:抗病毒治疗开发的重点靶点","authors":"Kavitha Karunakaran,&nbsp;Abdul Ajees Abdul Salam,&nbsp;Piya Paul Mudgal","doi":"10.1007/s00705-025-06325-2","DOIUrl":null,"url":null,"abstract":"<div><p>Chikungunya disease is spread by the bite of infected <i>Aedes</i> mosquitoes. It is considered a neglected tropical disease that has the potential to cause sporadic epidemics in naive populations. Despite the substantial investment in research, there are no approved antiviral treatments for chikungunya. Several screening approaches have been used to identify potential antiviral molecules that target the whole virus, viral proteins, and viral-host interactions, often in conjunction with computational studies. The genome of chikungunya virus (CHIKV) encodes four nonstructural and five structural proteins. The capsid protein (CP) is a small structural protein with enzymatic activity. Owing to its critical role in different stages of the viral life cycle, the CP can be targeted at multiple stages, thereby impeding viral multiplication. There is evidence suggesting that the CP may be a promising target for drug development, and this has led to the discovery of various inhibitors through diverse in vitro and in silico analyses. Both cell-based and cell-free assays have been widely used to identify and evaluate CHIKV CP inhibitors. Computer-based studies targeting CHIKV proteins, including CP, have identified several lead compounds, which are being further evaluated in various in vitro systems. No review has been published on the CHIKV CP, and papers have focused on drug development and the targeting of viral proteins and associated factors. In this review, we summarize the research that has been conducted on the CHIKV CP, including structural studies, antiviral research, and prospects for the use of the CP as an antiviral target.</p></div>","PeriodicalId":8359,"journal":{"name":"Archives of Virology","volume":"170 7","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploiting the chikungunya virus capsid protein: a focused target for antiviral therapeutic development\",\"authors\":\"Kavitha Karunakaran,&nbsp;Abdul Ajees Abdul Salam,&nbsp;Piya Paul Mudgal\",\"doi\":\"10.1007/s00705-025-06325-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Chikungunya disease is spread by the bite of infected <i>Aedes</i> mosquitoes. It is considered a neglected tropical disease that has the potential to cause sporadic epidemics in naive populations. Despite the substantial investment in research, there are no approved antiviral treatments for chikungunya. Several screening approaches have been used to identify potential antiviral molecules that target the whole virus, viral proteins, and viral-host interactions, often in conjunction with computational studies. The genome of chikungunya virus (CHIKV) encodes four nonstructural and five structural proteins. The capsid protein (CP) is a small structural protein with enzymatic activity. Owing to its critical role in different stages of the viral life cycle, the CP can be targeted at multiple stages, thereby impeding viral multiplication. There is evidence suggesting that the CP may be a promising target for drug development, and this has led to the discovery of various inhibitors through diverse in vitro and in silico analyses. Both cell-based and cell-free assays have been widely used to identify and evaluate CHIKV CP inhibitors. Computer-based studies targeting CHIKV proteins, including CP, have identified several lead compounds, which are being further evaluated in various in vitro systems. No review has been published on the CHIKV CP, and papers have focused on drug development and the targeting of viral proteins and associated factors. In this review, we summarize the research that has been conducted on the CHIKV CP, including structural studies, antiviral research, and prospects for the use of the CP as an antiviral target.</p></div>\",\"PeriodicalId\":8359,\"journal\":{\"name\":\"Archives of Virology\",\"volume\":\"170 7\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s00705-025-06325-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Virology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00705-025-06325-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

基孔肯雅病通过受感染的伊蚊叮咬传播。它被认为是一种被忽视的热带病,有可能在幼稚人群中引起散发的流行病。尽管在研究方面投入了大量资金,但基孔肯雅病还没有获得批准的抗病毒治疗方法。几种筛选方法已被用于识别针对整个病毒、病毒蛋白和病毒-宿主相互作用的潜在抗病毒分子,通常与计算研究相结合。基孔肯雅病毒(CHIKV)基因组编码4种非结构蛋白和5种结构蛋白。衣壳蛋白是一种具有酶活性的小结构蛋白。由于其在病毒生命周期的不同阶段发挥着关键作用,CP可以在多个阶段被靶向,从而阻止病毒增殖。有证据表明,CP可能是药物开发的一个有希望的目标,这导致通过不同的体外和计算机分析发现了各种抑制剂。基于细胞和无细胞的测定法已广泛用于鉴定和评价CHIKV CP抑制剂。针对CHIKV蛋白(包括CP)的计算机研究已经确定了几种先导化合物,这些化合物正在各种体外系统中进行进一步评估。没有关于CHIKV CP的综述发表,论文的重点是药物开发和病毒蛋白及相关因子的靶向。本文综述了CHIKV病毒CP的结构研究、抗病毒研究以及作为抗病毒靶点的应用前景等方面的研究进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploiting the chikungunya virus capsid protein: a focused target for antiviral therapeutic development

Chikungunya disease is spread by the bite of infected Aedes mosquitoes. It is considered a neglected tropical disease that has the potential to cause sporadic epidemics in naive populations. Despite the substantial investment in research, there are no approved antiviral treatments for chikungunya. Several screening approaches have been used to identify potential antiviral molecules that target the whole virus, viral proteins, and viral-host interactions, often in conjunction with computational studies. The genome of chikungunya virus (CHIKV) encodes four nonstructural and five structural proteins. The capsid protein (CP) is a small structural protein with enzymatic activity. Owing to its critical role in different stages of the viral life cycle, the CP can be targeted at multiple stages, thereby impeding viral multiplication. There is evidence suggesting that the CP may be a promising target for drug development, and this has led to the discovery of various inhibitors through diverse in vitro and in silico analyses. Both cell-based and cell-free assays have been widely used to identify and evaluate CHIKV CP inhibitors. Computer-based studies targeting CHIKV proteins, including CP, have identified several lead compounds, which are being further evaluated in various in vitro systems. No review has been published on the CHIKV CP, and papers have focused on drug development and the targeting of viral proteins and associated factors. In this review, we summarize the research that has been conducted on the CHIKV CP, including structural studies, antiviral research, and prospects for the use of the CP as an antiviral target.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Virology
Archives of Virology 医学-病毒学
CiteScore
5.10
自引率
7.40%
发文量
324
审稿时长
4.5 months
期刊介绍: Archives of Virology publishes original contributions from all branches of research on viruses, virus-like agents, and virus infections of humans, animals, plants, insects, and bacteria. Coverage spans a broad spectrum of topics, from descriptions of newly discovered viruses, to studies of virus structure, composition, and genetics, to studies of virus interactions with host cells, organisms and populations. Studies employ molecular biologic, molecular genetics, and current immunologic and epidemiologic approaches. Contents include studies on the molecular pathogenesis, pathophysiology, and genetics of virus infections in individual hosts, and studies on the molecular epidemiology of virus infections in populations. Also included are studies involving applied research such as diagnostic technology development, monoclonal antibody panel development, vaccine development, and antiviral drug development.Archives of Virology wishes to publish obituaries of recently deceased well-known virologists and leading figures in virology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信